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S
ince its earliest description several
thousand years ago, diabetes has re-
mained a chronic progressive dis-
ease (1). The disease now affects 200
million people worldwide, and diabetes-
related death is expected to increase by
50% in the next 10 years (2). The situ-
ation is only getting worse. The preva-
lence of diabetes among the elderly has
increased 63% in the 10 years 1994–
2004 (3). This increasing prevalence is a
testament to improvement in managing
diabetes-related complications, as well as
our global “modernization” and the ac-
companying metabolic derangements.
Diabetes is now ranked as the sixth lead-
ing cause of death by disease in the U.S.
(4). In many places, it ranks far higher.
The economic burden in 2007 alone ex-
ceeded $174 billion (5).
Diet modiﬁcation and oral hypogly-
cemic medications have proven inade-
quate, whereas insulin therapy only
solves the problem temporarily. In the
U.K. Prospective Diabetes Study, diabetic
patients were treated with diet modiﬁca-
tion, metformin, sulfonylurea, or insulin.
Consistent with the progressive nature of
diabetes,monotherapywasabandonedin
75%ofthepatientsstudiedinafollow-up
of9years(6).Evenwiththenewestphar-
maco-therapies, patients continue to
develop macro- and microvascular com-
plications. Diabetes is associated with in-
creased cardiac- and stroke-related
deaths, kidney failure, blindness, and
60% of nontrauma lower-limb amputa-
tions (4). In cardiac surgery, diabetes as a
preoperative risk factor confers greater
morbidity than a previous myocardial in-
farction (7,8).
While these numbers show that dia-
betes will be the global health crisis of the
next generation, its true pathophysiology
has yet to be delineated. Alternative treat-
ments targeting different models of this
disease require careful and responsible
examination. A large body of evidence
now demonstrates surgery for type 2 dia-
betes can achieve up to complete disease
remission, a goal almost unheard of in
current diabetes care. Evidence collected
over decades of bariatric surgery demon-
strates the effectiveness and durability of
diabetes control gained after gastrointes-
tinal bypass surgeries (9–13). “Metabolic
surgery” is now emerging as an area ded-
icated to the establishment of surgical
procedures speciﬁcally aimed at treating
diabetes. This article will focus on the ra-
tionale for surgery as a new therapy for
type 2 diabetes and explore the various
surgical options currently available and
those under investigation.
EVIDENCE— In the early 1980s, sur-
geons realized that many patients with
type 2 diabetes who had undergone gas-
tric bypass for the treatment of morbid
obesity experienced a complete diabetes
remission.Thisremissionproveddurable
(11,14,15). Since then, there have been
many studies conﬁrming the efﬁcacy of
bariatric procedures in treating type 2 di-
abetes. In the meta-analysis of 22,094 pa-
tients,Buchwaldetal.(11)founddiabetes
resolution in 98.9% of patients undergo-
ing biliopancreatic diversion or duodenal
switch, 83.7% resolution after gastric by-
pass,and47.9%afterlaparoscopicgastric
banding. In the Swedish Obesity Study, a
prospective case-matched investigation
compared obese patients undergoing gas-
tric banding, vertical banded gastro-
plasty, or gastric bypass with obese
control subjects maintained with conven-
tional treatment. The data were collected
for 4,047 patients who were followed for
over 2 years, with 1,703 followed over 10
years. The incidence of diabetes at 2 and
10 years was signiﬁcantly lower in the
surgery group, 1 and 7%, respectively,
comparedwiththecontrolsubjects,8and
24% (P  0.001). Diabetes remission
rates at 2 and 10 years were 72 and 37%
after surgery and 21 and 13% with med-
ical therapy (12). Many have commented
that the 10-year remission rate of the
Swedish Obesity Study is lower than ex-
pected because of the high percentage of
purely restrictive procedures performed
on that population (vertical banded gas-
troplastyandgastricbanding),operations
less effective for diabetes resolution.
Diabetescontrolandremissionseems
to be best obtained with procedures that
include an intestinal bypass, as in gastric
bypass or biliopancreatic diversion. With
a 14-year follow-up, Pories et al. (14)
found an 83% resolution of type 2 diabe-
tes in 608 patients after gastric bypass.
These data were conﬁrmed by Schauer et
al.(10)withthesame83%resolutionrate
in 240 obese patients undergoing laparo-
scopic gastric bypass. Scopinaro et al.
(16) reported a 97% diabetes remission
rate in 312 patients maintained at 10
years postoperative follow-up. Purely re-
strictive procedures also signiﬁcantly im-
prove diabetes, although seemingly less
effectively than bypass operations. Their
efﬁcacy relies more on decreased calorie
intake and weight loss to ameliorate the
diabetes. Remission is typically not seen
until several months postoperatively,
only once weight loss has occurred (17).
In a recent clinical study, resolution of
diabetes after gastric banding was
strongly correlated with amount of
weight lost, and none of the patients in
this study experienced remission before 6
months (18).
The mechanism of diabetes resolu-
tion after gastrointestinal bypass remains
unclear but is apparently not related to
weight loss alone. In most cases, remis-
sion is observed in the days to weeks after
surgery before any substantial weight loss
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Department of Surgery, Sanford I. Weill Medical College of Cornell University, New York-
Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
Corresponding author: Francesco Rubino, frr2007@med.cornell.edu.
The publication of this supplement was made possible in part by unrestricted educational grants from Eli
Lilly,EthiconEndo-Surgery,GenerexBiotechnology,Hoffmann-LaRoche,Johnson&Johnson,LifeScan,
Medtronic, MSD, Novo Nordisk, Pﬁzer, sanoﬁ-aventis, and WorldWIDE.
DOI: 10.2337/dc09-S341
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
OBESITY AND LIPIDS
S368 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.orghas occurred (10,15,19). Furthermore,
emerging evidence now shows that these
effects may be achievable in the nonobese
populationaswell.Severalhumanstudies
have shown dramatic diabetes control in
patients with BMI 35 kg/m
2 (20,21).
Lee et al. (22) showed that 89.5% of dia-
betic patients with BMI 35 kg/m
2 had
returnedtoeuglycemiaat1yearaftergas-
tric bypass. The mean A1C level was re-
duced from 7.3% preoperatively to 5.6%
at 1 year after surgery.
Theseclinicaldatacorroborateearlier
animal ﬁndings showing that surgical
control of diabetes can be obtained in
both obese and nonobese rodents (23).
Clinical studies also show that the effect
on diabetes after gastric bypass proce-
dures does not depend only on the
amount of weight loss (24,25). The an-
tidiabetic mechanism of the surgery may
be from a combination of hormonal
changes seen after exclusion of the prox-
imal intestine and increasing nutrient de-
livery to the distal small bowel. Both
mechanisms are currently being investi-
gated (26,27).
Given the success of bariatric surger-
ies in treating diabetes, should we now
movetowardtheestablishmentofspeciﬁc
surgicalinterventionstotreatdiabetes?As
with all other surgical procedures, the
beneﬁts of surgery must be weighed
againstthepotentialrisks.Inotherwords,
one must consider the possible compli-
cations and mortality of surgery versus
the probable remission of diabetes and
decrease in lifelong diabetes-related
morbidity and mortality. Contrary to
commonly held misperceptions, bariatric
surgeryhasastrikinglysafeoperativepro-
ﬁle and associated low mortality. In the
Buchwald meta-analysis of 361 studies
encompassing 85,048 patients, early
(30 days) or late (30 days to 2 years)
mortalitywas0.28%(95%CI0.22–0.34)
and 0.35% (0.12–0.58) (28). This is in
line with more recent studies that report
bariatric surgery mortality rates ranging
from 0.25 to 0.5% (28–31). These good
numbers likely reﬂect a move by most
centers toward a predominantly laparo-
scopic technique, the implemented sys-
tem of wide controls, and incorporation
of a multidisciplinary approach (32,33).
These mortality rates are comparable to
thoseofpatientsundergoinglaparoscopic
cholecystectomy (0.26–0.6%), a com-
monly performed elective procedure
(34).
In the medical community, as well as
in the general public, cholecystectomy is
generally considered a safe and routine
procedure, whereas bariatric surgery is
often seen as extreme and dangerous.
While obesity has only recently become
accepted as a genuine disease, bariatric
surgery continues to be considered as too
drastic a measure as elective treatment,
although data show it is as safe or even
safer compared with most other surgical
interventions. The mortality rates of cor-
onaryarterybypassgraftforthetreatment
of coronary artery disease are reported to
be on average 3.5% (30). If the risk asso-
ciatedwithsurgicaltreatmentofcoronary
artery disease (a chronic progressive dis-
ease with no known cure) is acceptable,
then the 0.5% risk of gastrointestinal by-
pass surgery should not be seen as a dras-
ticmeasuretotreatpatientswithdiabetes.
Mortality in a vacuum should not be a
deterrent to surgery, but rather should be
weighed against the potential long-term
beneﬁts conferred and the low proce-
dure-related complication rates (32).
Thebeneﬁtsofdiabetesresolutionac-
complishedbysurgeryaresigniﬁcant.Di-
abetes-related mortality after Roux-en-Y
gastric bypass has been followed over a
periodof7yearsanddecreased92%com-
pared with controls (35). In a retrospec-
tive review of 23,803 morbidly obese
patients, 5,347 of whom had diabetes,
survival rates were increased, and the
presence of comorbidities decreased in
surgical patients compared with the non-
surgical group (P  0.001). This survival
beneﬁt occurred as early as 6 months for
patients under 65 years and at 11 months
for patients older than 65 years (36). An-
other beneﬁt of the surgery is the general
improvement in metabolic syndrome,
whichcontributestoadecreaseincardio-
vascular risk factors. Studies have shown
a signiﬁcant improvement in all compo-
nents of the metabolic syndrome (type 2
diabetes, hypertension, increased fasting
glucoseandtriglycerides,decreasedHDL,
and abdominal obesity) and an overall
resolution of 95.6% at 1 year (37–40).
Despite the compelling outcome data, the
decisiontooperateshouldbemadebased
on a risk factor assessment for each
patient.
DIABETES SURGERY: A
NEW DISCIPLINE?— While con-
ventional bariatric surgery seems to treat
diabetes, many are evaluating procedures
speciﬁcally geared to treat diabetes on its
own. Conventional operations already in
practice addressing obesity include lapa-
roscopic adjustable gastric banding,
Roux-en-Y gastric bypass, biliopancreatic
diversion with duodenal switch, and
sleeve gastrectomy. Laparoscopic ad-
justable gastric banding is strictly re-
strictive, with the band wrapping the
proximal stomach, just below the gas-
tro-esophageal junction. The patient
loses weight because he or she feels full
early with distension of the banded stom-
ach after a few bites of food. The amount
of gastric restriction can be adjusted
basedoninjectionorwithdrawalofsaline
from within the inﬂatable plastic core.
Roux-en-Y gastric bypass provides re-
striction via a small vertically oriented
gastricpouchalongthelessercurvatureof
the stomach. The jejunum is divided and
rerouted to reestablish gastrointestinal
continuity and allow nutrients to bypass
theduodenumandproximalsmallbowel.
The biliopancreatic diversion in its “duo-
dena switch” variant consists of a vertical
gastrectomy (“sleeve gastrectomy”) and
an extensive bypass of the bowel, with a
duodeno-ileostomy leaving only a short
segment for absorption. The sleeve gas-
trectomy component of the biliopancre-
atic diversion with duodenal switch has
been recently found to be effective as a
stand-alone procedure in many over-
weightindividuals(41).Becauseamalab-
sorptive component is missing, attention
is paid to making a narrow sleeve and re-
secting the ghrelin-producing fundus to
limit stomach dilation and weight regain.
Novel operations are geared toward
the treatment of diabetes and not neces-
sarily to induce weight loss. Among the
most prominent of these operations are
the duodenal-jejunal bypass and ileal
transposition. Duodenal-jejunal bypass is
a stomach sparing bypass of a short seg-
ment of the proximal intestine, a gastric
bypass without the stomach stapling. Du-
odenal-jejunal bypass has been shown to
improve diabetes in both lean and obese
animal models (23). It is currently being
investigated in select early human trials.
Published data on a sampling of cases
shows that normal-weight type 2 diabetic
patientsundergoingduodenal-jejunalby-
pass had normalized fasting blood glu-
cose levels 100 mg/dl. A1C dropped to
6%, from a preoperative level of 8–9%
(20). It is expected that this procedure
might duplicate the well-described safety
proﬁle of the Roux-en-Y gastric bypass.
Ileal interposition, previously called
“transposition,” is another procedure be-
ing investigated to treat type 2 diabetes.
Ilealtranspositioninvolvestheremovalof
a small segment of the ileum with its vas-
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into the proximal small intestine. Animal
studies of ileal transposition show exag-
geratedreleaseofthegastrointestinalhor-
mone glucagon like peptide-1. Glucagon
like peptide-1 is a potent insulinotropic
hormone that improves glucose toler-
ance, this action being used in drug ther-
apy for diabetes (42,43). Early human
studies with ileal transposition show
promise, and the procedure is often com-
bined with a sleeve gastrectomy when
weight loss is desired. In a study of 60
patients with diabetes and BMI ranging
from 23.6 to 34.4 kg/m
2, 86.7% achieved
glycemic control at a mean follow-up of
7.4 months (44). The exact mechanism at
work in this surgery is unclear, and dia-
betes improvement may be due to weight
loss, the neurohormonal changes that ac-
company rearrangement of the intestine,
or a combination of the two. Long-term
outcomes of this operation regarding
safety as well as metabolic complications
have yet to be reported.
Another novel procedure is the en-
doluminal duodenal-jejunal bypass
sleeve. This procedure entails the endo-
scopicdeliveryandanchoringofaplastic-
coated sleeve implant that extends into
the jejunum and effectively excludes the
duodenum. The device theoretically
mimics the duodenal-jejunal bypass, in
thatnutrientspassthroughouttheduode-
num without contact with its mucosa,
while the distal small bowel receives less
processed foodstuffs. The endoluminal
duodenal-jejunal bypass sleeve is able to
do this without disrupting bowel conti-
nuity or creating new anastomosis. This
method has been shown to improve dia-
betes in lean rodents (F.R., personal com-
munication).Tarnoffetal.(45–47)tested
the feasibility of the endoluminal duode-
nal-jejunal bypass sleeve in a porcine an-
imal model, and results from the ﬁrst
human experiments were recently pub-
lished. Twelve morbidly obese patients,
four with diabetes, underwent endo-
scopic placement of the duodenal sleeve.
The study duration was 12 weeks, with
17%requiringsleeveretrieval.Allfourdi-
abetic patients were able to maintain nor-
mal fasting plasma glucose without
medication for the 12 weeks of the study,
and three patients had a 0.5% decrease in
A1C by week 12 (47). The safety and ef-
ﬁcacy of long-term device placement in
humans has not been fully established,
but in terms of effectiveness and applica-
bility, these preliminary results are
promising.
SURGERY FOR DIABETES:
OPPORTUNITIES,
BARRIERS, AND
LIMITATIONS— The notion of sur-
geryfordiabetesbringswithitcertainun-
derstandings. First, surgery is by design
an invasive treatment modality and car-
ries risks related to both anesthesia and
the procedure itself. Like with all other
surgical treatments, patients will have to
be carefully screened. For instance, not
every patient with carotid stenosis merits
or warrants an endarterectomy; likewise,
a surgical treatment for diabetes is not for
everyone. Furthermore, with our current
limitedknowledge,itisnotyetpossibleto
deﬁneexactindicationsandcontraindica-
tions to surgery. With the need for guide-
lines and recommendations, the Diabetes
Surgery Summit, a collaborative consen-
sus conference including top interna-
tional endocrinologists and surgeons,
convened in Rome last year to address
some of these issues. The position state-
ment from the Diabetes Surgery Summit
(submitted for publication at the time of
this writing) promises to represent the
foundation of a new discipline and pro-
vides a multidisciplinary scientiﬁcally
solidgroundedapproachfromtheoutset.
At this time, few people who want di-
abetes surgery have access to it, and the
majority of those with access have not
chosen it. The development of diabetes
surgerywillhavetoovercomeseveralbar-
riers, including the ingrained notion of
diabetes as strictly a medical disease. Fi-
nancial issues will also have to be ad-
dressed. Major insurance companies in
the U.S. today will only cover surgical in-
tervention for the treatment of diabetes
for patients with a BMI35 kg/m
2. How-
ever, even among patients who are al-
ready eligible under current National
Institutes of Health criteria, barely 1% are
usually referred for surgical treatment
(48).Thisisduetoseveralreasonsinclud-
ingreluctanceofmajorinsuranceplansto
cover the procedures. For nearly all those
withouttheappropriatelevelofhealthin-
surance coverage or those cursed with
only mild obesity, the surgical option for
diabetes treatment is impossible. How-
ever, new studies reveal that surgery for
diabetes and obesity is indeed cost-
effective (49). Another barrier to over-
come may be the lack of an adequate
workforce of trained bariatric surgeons in
advanced laparoscopy to perform meta-
bolic surgery. However, general surgeons
too may have the opportunity to learn the
skills to safely and effectively provide so
potentially valuable a tool in the treat-
ment of such a prevalent disease.
Surgery seems to provide an addi-
tionalweaponagainstdiabetes.Theuseof
metabolic surgery has caused a redeﬁni-
tion of diabetes treatment goals, from
controltoremission.Thepotentialofsur-
gery to delineate the complex physiology
of the neurohormonal axes within the
gastrointestinal tract may lead to an im-
proved understanding of the same patho-
physiology of diabetes. This can in turn
lead to new targets for medical and inter-
ventional therapies. In the end, it may be
a combination of surgical therapy and
medical management that provides the
best long-term outcomes in these pa-
tients.Thisisaroadwelltreadinthetreat-
ment of cancer and cardiac diseases.
CONCLUSIONS — The economic,
medical, and social burden of diabetes is
immense. Given our current inability to
achieve major remission and reduce
death rates with medical management,
metabolic surgery represents a new fron-
tier in diabetic treatment. Over the past
20years,bariatricsurgeryhasprovensuc-
cessfulintreatingnotjustobesitybutalso
type 2 diabetes. Surgery should now be
looked at as a viable therapy for not only
the morbidly obese, but also for diabetic
patients who fall outside current BMI
guidelines. The potential beneﬁts of met-
abolicsurgeryareinfactenormous.How-
ever, its implementation requires a
rethinking of diabetes treatments goals
and strategies. In the meantime, investi-
gation into the pathophysiological basis
of diabetes continues, with the hope of
discovering the optimal therapeutic tar-
gets and best-suited interventions.
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